Xiaozhuo Liu

This study quantifies cancer stemness in prostate cancer across progression stages, showing its association with therapy resistance, poor survival, and lineage plasticity.

The paper identifies eIF1A methylation sites and shows that methylation at R13 and R14 improves start codon recognition fidelity in yeast.

This study identifies STAG2's role in regulating chromatin architecture and gene expression in muscle invasive bladder cancer, revealing its context-specific activation and repression of genes involved in oncogenic signaling.

This study identifies an opioid-mediated signaling axis in pancreatic cancer that drives extracellular matrix remodeling and tumor aggressiveness, suggesting methylnaltrexone as a potential therapeutic.

This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.

The paper shows that loss of ATG5 in prostate cancers leads to tumor growth by accumulating p62, suggesting ATG5 acts as a tumor suppressor in this context.

This study evaluates folate-conjugated miR-34a as a potential prostate cancer therapeutic, finding limited efficacy due to low FOLR1 expression in prostate cancer cells.

This study identifies the N-terminal domain of eIF4B as critical for yeast growth under urea stress by enhancing translation of mRNAs with structured 5' UTRs.